Bank of America raised its price target for Gilead Sciences stock from USD 162.00 to USD 164.00 on October 12, 2026, while maintaining a Buy rating. The analyst view remains tied to the company's commercial execution rather than awaiting new corporate announcements. At the time of the report, Gilead Sciences stock was trading at approximately USD 156.34, placing the new target about 4.90 percent above the current market price. The revision is supported by BofA's modeling of third-quarter Biktarvy sales at USD 3.922 billion, which exceeds the consensus estimate of USD 3.908 billion by USD 14 million. This specific operating metric provides investors with a measurable reference point for the upcoming earnings release scheduled for October 29, 2026, after market close. As of mid-October 2026, Gilead Sciences holds a market capitalization of USD 193.9 billion and trades within a 52-week range of USD 114.02 to USD 160.51. The company's P/E ratio is listed as minus 58.60, reflecting its biotech sector status where earnings multiples may differ from traditional metrics due to significant R&D investments or specific accounting treatments.